Durability of Response in Children Treated with Pegylated Interferon alfa-2a +/- Ribavirin for Chronic Hepatitis C
dc.contributor.author | Schwarz, Kathleen B. | |
dc.contributor.author | Molleston, Jean P. | |
dc.contributor.author | Jonas, Maureen M. | |
dc.contributor.author | Wen, Jessica | |
dc.contributor.author | Murray, Karen F. | |
dc.contributor.author | Rosenthal, Philip | |
dc.contributor.author | Gonzalez-Peralta, Regino P. | |
dc.contributor.author | Lobritto, Steven J. | |
dc.contributor.author | Mogul, Douglas | |
dc.contributor.author | Pavlovic, Vedran | |
dc.contributor.author | Warne, Charles | |
dc.contributor.author | Wat, Cynthia | |
dc.contributor.author | Thompson, Bruce | |
dc.contributor.department | Department of Pediatrics, IU School of Medicine | en_US |
dc.date.accessioned | 2016-08-02T15:35:52Z | |
dc.date.available | 2016-08-02T15:35:52Z | |
dc.date.issued | 2016-01 | |
dc.description.abstract | Objectives: No long-term data have been published on the durability of response following pegylated interferon (PegIFN) treatment in children with chronic hepatitis C. This prospective, multicenter, long-term follow-up (LTFU) study aimed to assess long-term durability of sustained virological response (SVR), long-term safety and tolerability, and the association between IL28B genotype and treatment response, in children previously treated with PegIFN alfa-2a ± ribavirin (RBV) in the PEDS-C trial. Methods: A total of 93 patients were assessed for enrollment, and 38 enrolled in the study. Patients attended 2 study visits: 5 (mean 5.6, range 4.1–6.6) and 6 (6.6, 5.1–7.7) years after treatment cessation. Standardized medical history, physical examination, and laboratory testing were performed at these visits. Reminder telephone calls were conducted at 4 and 8 months after the initial visit. Results: The LTFU cohort was the representative of the original PEDS-C cohort because both baseline and treatment characteristics were comparable. Of the 38 participants, 21 achieved SVR (responders) during the PEDS-C trial and 17 had not (nonresponders). All 21 responders maintained undetectable hepatitis C virus RNA during the LTFU (4.4–7.0 years after achieving SVR) in contrast to the nonresponders who demonstrated persistent viremia. IL28B CC genotype was associated with SVR (67% vs 30% in non-CC, P = 0.028). Conclusion: Long-term durability of SVR is excellent following PegIFN alfa-2a treatment in children with chronic hepatitis C; SVR is higher in those with IL28B CC versus non-CC. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Schwarz, K. B., Molleston, J. P., Jonas, M. M., Wen, J., Murray, K. F., Rosenthal, P., … Thompson, B. (2016). Durability of Response in Children Treated with Pegylated Interferon alfa 2a +/− Ribavirin for Chronic Hepatitis C. Journal of Pediatric Gastroenterology and Nutrition, 62(1), 93–96. http://doi.org/10.1097/MPG.0000000000000929 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/10532 | |
dc.language.iso | en | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.relation.isversionof | 10.1097/MPG.0000000000000929 | en_US |
dc.relation.journal | Journal of Pediatric Gastroenterology and Nutrition | en_US |
dc.rights | IUPUI Open Access Policy | en_US |
dc.source | Author | en_US |
dc.subject | pediatric viral hepatitis | en_US |
dc.subject | antiviral therapy | en_US |
dc.subject | PEDS C study | en_US |
dc.title | Durability of Response in Children Treated with Pegylated Interferon alfa-2a +/- Ribavirin for Chronic Hepatitis C | en_US |
dc.type | Article | en_US |